Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG2 | P78540 | 10/20 | 0.50 |
| ▸ | ARG1 | P05089 | 10/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL894245 | 0.99 | ARG2 (0.49) | ARG2ARG1KDM4EALDH1A1GAA | |
| SCHEMBL1740773 | 0.97 | ARG2 (0.53) | ARG2ARG1KDM4EALDH1A1GAA | |
| SCHEMBL1742309 | 0.86 | ARG1 (0.55) | ARG2ARG1 | |
| SCHEMBL1740677 | 0.85 | ARG1 (0.51) | ARG2ARG1KDM4E | |
| Hydrochloric Acid SCHEMBL1740818 | 0.85 | ARG1 (0.54) | ARG2ARG1 | |
| SCHEMBL1742349 | 0.85 | ARG1 (0.56) | ARG2ARG1KDM4EALDH1A1 | |
| SCHEMBL20683368 | 0.85 | L3MBTL1 (0.46) | KDM4EALDH1A1GAA | |
| SCHEMBL1739394 | 0.84 | ARG1 (0.56) | ARG2ARG1 | |
| Trifluoroacetic Acid SCHEMBL3420542 | 0.82 | ARG1 (0.59) | ARG2ARG1 | |
| SCHEMBL13251231 | 0.82 | ARG1 (0.64) | ARG2ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023283332-A1 | USES OF ARGINASE INHIBITORS FOR MANAGING KIDNEY DISEASE AND CARDIOVASCULAR CONDITIONS | EMORY UNIVERSITY (US) | 2023-01-12 | — | — | WO | disclosed |
| US-20190343852-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | CALITHERA BIOSCIENCES, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| WO-2011133653-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343852-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | ARG1, ARG2, PRMT3 | ARG2 2/4885ARG1 1/4885KDM4E 1380/4885 |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG2 2/4885ARG1 1/4885KDM4E 804/4885 |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG2 2/4885ARG1 1/4885KDM4E 804/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG2 2/4885ARG1 1/4885KDM4E 804/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG2 2/4885ARG1 1/4885KDM4E 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.